

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

(Present Status of Competition in the Pharmaceutical Industry)

WEDNESDAY, NOVEMBER 10, 1976

**U.S. SENATE,
SUBCOMMITTEE ON MONOPOLY OF THE
SELECT COMMITTEE ON SMALL BUSINESS,
Washington, D.C.**

The subcommittee met, pursuant to recess, at 10 a.m., in room 318, Russell Senate Office Building, Hon. Gaylord Nelson, chairman, presiding.

Present: Senator Nelson.

Also present: Benjamin Gordon, staff economist; and Karen Young, research assistant.

Senator NELSON. The subcommittee will please come to order.

Our first witness today is Dr. Donald R. Jasinski, chief of the clinical pharmacology section of the National Institute on Drug Abuse, Addiction Research Center, Lexington, Ky.

Dr. Jasinski, we are pleased to have you here today, and appreciate your taking time to present your testimony.

Your statement will be printed in full in the record, and you may present it however you desire.

STATEMENT OF DONALD R. JASINSKI, M.D., CHIEF, CLINICAL PHARMACOLOGY SECTION, NATIONAL INSTITUTE ON DRUG ABUSE, ADDICTION RESEARCH CENTER, LEXINGTON, KY.

Dr. JASINSKI. I choose to read the statement.

Senator NELSON. Fine.

Then please proceed.

Dr. JASINSKI. Mr. Chairman and members of the subcommittee, my name is Donald R. Jasinski. I am a physician who is a commissioned officer in the U.S. Public Health Service.

I hold the position of Chief, Clinical Pharmacology Section, of the National Institute on Drug Abuse Addiction Research Center, Lexington, Ky.

For over 40 years, the Addiction Research Center has conducted studies in volunteer prisoner addicts to assess the abuse potential of psychoactive drugs proposed for introduction into therapeutics.

Such studies with narcotic analgesics have proven to be a valid means of protecting the public health.